Default company panoramic image
Logo

bioMetric Holdings, Inc.

Developing a disruptive long-term micro optical sensor providing user with real time qualitative & quantitative glucose info on demand

  • Stage Product In Development
  • Industry Biotechnology
  • Location Portland, OR, USA
  • Currency USD
  • Founded January 2012
  • Employees 4

Company Summary

Developing a user-friendly optical glucose sensor dwelling in the dermis for 29 days (1st gen). Device, proven in animals, indicates qualitative glucose based on color seen through the skin, or on quantitative basis with smart phone app & camera imaging site, displaying data on screen, storing data in the cloud, and providing user painless means to manage diabetes any time of day, or continuously, thus facilitating management of diabetes.

Team

  • Default avatar
    Richard Guy Sass, FRSA
    Chairman,CEO & President

    Serial product development and manufacturing Entrepreneur with 48 years experience guiding innovative technology companies from inception to exit, primarily medical electronics.Past 19 years focused on diabetes industry. Directed over $150 million in exits with 3 companies, most recent exit to Bayer Healthcare. Successful application engineering and technology transfer negotiation for technologies addressing large unmet needs in Healthcare.

  • Default avatar
    Jane Karen Conner, CPA, MBA
    Chief Financial Officer

    Proven track record in operational leadership and financial management during her
    34-year career, which includes both entrepreneurial and highly-structured environments, including 19 years as a financial executive in the Diabetes industry. Significant experience with strategic planning and business development. Upon acquisition, led integration of start-up co into Bayer. Skilled in IP mgmt, contracts admin & forecasting incl $138 million in exit

  • Default avatar
    Mihailo V. Rebec, PhD
    Chief Technology Officer

    Over 30 years of medical device R&D, including 20+ as Sr. Scientist in advanced technology group of Bayer. Expertise in analytical methods related to development of medical diagnostics, early phase product research, infrared analysis, quality control, data analysis, algorithm development, instrumentation development, regulatory issues, regulatory submissions including FDA, clinical testing and studies, design of animal studies, ACLAC submissions

Previous Investors

  • Default avatar
    Richard G. Sass
    Unconfirmed
    Default avatar
    Jane K. Conner
    Unconfirmed
    Default avatar
    Mihailo V. Rebec
    Unconfirmed